Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Trevi Therapeutics Inc’s stock clocked out at $6.59, up 1.85% from its previous closing price of $6.47. In other words, the price has increased by $1.85 from its previous closing price. On the day, 1.49 million shares were traded. TRVI stock price reached its highest trading level at $6.7 during the session, while it also had its lowest trading level at $6.39.
Ratios:
To gain a deeper understanding of TRVI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.41 and its Current Ratio is at 10.41. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Raymond James on March 10, 2025, Upgraded its rating to Strong Buy and sets its target price to $29 from $9 previously.
On March 10, 2025, Needham reiterated its Buy rating and also lowered its target price recommendation from $8 to $25.
H.C. Wainwright reiterated its Buy rating for the stock on December 12, 2024, while the target price for the stock was revised from $6 to $7.50.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 25 ’25 when SCIASCIA THOMAS sold 2,631 shares for $6.60 per share. The transaction valued at 17,365 led to the insider holds 221,373 shares of the business.
GOOD JENNIFER L sold 5,263 shares of TRVI for $34,625 on Mar 21 ’25. The President & CEO now owns 213,313 shares after completing the transaction at $6.58 per share. On Mar 21 ’25, another insider, GOOD JENNIFER L, who serves as the Officer of the company, bought 5,263 shares for $6.58 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRVI now has a Market Capitalization of 637135744 and an Enterprise Value of 530545888.
Stock Price History:
The Beta on a monthly basis for TRVI is 0.63, which has changed by 1.2491467 over the last 52 weeks, in comparison to a change of 0.097913146 over the same period for the S&P500. Over the past 52 weeks, TRVI has reached a high of $7.39, while it has fallen to a 52-week low of $2.30. The 50-Day Moving Average of the stock is 16.12%, while the 200-Day Moving Average is calculated to be 69.75%.
Shares Statistics:
It appears that TRVI traded 2.16M shares on average per day over the past three months and 995930 shares per day over the past ten days. A total of 93.60M shares are outstanding, with a floating share count of 57.14M. Insiders hold about 40.90% of the company’s shares, while institutions hold 45.73% stake in the company. Shares short for TRVI as of 1744675200 were 5911171 with a Short Ratio of 2.73, compared to 1741910400 on 4676973. Therefore, it implies a Short% of Shares Outstanding of 5911171 and a Short% of Float of 8.53.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
